What is Noble Life Sciences?
Noble Life Sciences operates as a full-service preclinical contract research organization (CRO), dedicated to expediting the journey of novel drugs and medical devices from concept to market. The company offers a broad spectrum of services, including Good Laboratory Practice (GLP) and non-GLP studies, advanced bioanalysis, pharmacodynamic modeling, and rigorous preclinical safety testing. Its expertise spans critical therapeutic areas such as oncology and infectious diseases, as well as the development of biologics, cell and gene therapies, and medical devices. By providing end-to-end support throughout the preclinical lifecycle, Noble Life Sciences aims to mitigate development risks and streamline the path to regulatory approval for its clients.
How much funding has Noble Life Sciences raised?
Noble Life Sciences has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Noble Life Sciences
PPP
Public-Private Partnership
What's next for Noble Life Sciences?
The substantial large-scale late-stage funding positions Noble Life Sciences for significant expansion and enhanced service offerings. This capital infusion is expected to fuel advancements in their research capabilities, potentially broadening their service portfolio to encompass more complex therapeutic modalities and advanced testing methodologies. The strategic investment signals strong confidence from backers in Noble Life Sciences' business model and its capacity to capture a larger share of the growing preclinical CRO market. Future growth will likely involve scaling operations to meet increasing demand, investing in cutting-edge technologies, and potentially forging new strategic partnerships to further solidify its market leadership in preclinical drug and device development.
See full Noble Life Sciences company page
